JP2006249089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006249089A5 JP2006249089A5 JP2006065731A JP2006065731A JP2006249089A5 JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5 JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- imidazo
- pyridin
- carbonyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyridin-1-yl Chemical group 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66059205P | 2005-03-11 | 2005-03-11 | |
| US60/660,592 | 2005-03-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006249089A JP2006249089A (ja) | 2006-09-21 |
| JP2006249089A5 true JP2006249089A5 (OSRAM) | 2009-04-16 |
| JP5069415B2 JP5069415B2 (ja) | 2012-11-07 |
Family
ID=36649530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006065731A Active JP5069415B2 (ja) | 2005-03-11 | 2006-03-10 | 結晶形態のイミダゾール誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7960407B2 (OSRAM) |
| EP (1) | EP1861400B1 (OSRAM) |
| JP (1) | JP5069415B2 (OSRAM) |
| KR (1) | KR100911073B1 (OSRAM) |
| CN (1) | CN101137656B (OSRAM) |
| AR (1) | AR055567A1 (OSRAM) |
| AT (1) | ATE469150T1 (OSRAM) |
| AU (1) | AU2006221699A1 (OSRAM) |
| BR (1) | BRPI0608819B8 (OSRAM) |
| CA (1) | CA2600510C (OSRAM) |
| DE (1) | DE602006014516D1 (OSRAM) |
| ES (1) | ES2344310T3 (OSRAM) |
| IL (1) | IL185145A0 (OSRAM) |
| IN (1) | IN2014DN09939A (OSRAM) |
| MX (1) | MX2007011110A (OSRAM) |
| NL (1) | NL300944I2 (OSRAM) |
| PL (1) | PL1861400T3 (OSRAM) |
| RU (1) | RU2357968C1 (OSRAM) |
| TW (1) | TW200643021A (OSRAM) |
| WO (1) | WO2006095268A1 (OSRAM) |
| ZA (1) | ZA200707568B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009295308A1 (en) * | 2008-09-25 | 2010-04-01 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists |
| ES2960438T3 (es) | 2009-04-22 | 2024-03-04 | Askat Inc | Sustancia antagonista del receptor EP4 selectivo para el tratamiento del cáncer |
| BR112012020236A2 (pt) * | 2010-02-22 | 2016-05-17 | Raqualia Pharma Inc | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero |
| RU2451680C1 (ru) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство |
| RU2464042C1 (ru) * | 2011-03-31 | 2012-10-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО |
| US20160317514A1 (en) * | 2013-03-19 | 2016-11-03 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of cartilage disease |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| PT3113774T (pt) | 2014-03-06 | 2022-02-28 | Elanco Animal Health Incorporated | Composições de grapiprant e métodos de utilização das mesmas |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| JP6535683B2 (ja) * | 2014-03-06 | 2019-06-26 | アラタナ セラピューティクス、 インコーポレイテッド | グラピプラントの結晶型 |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| JP2021522211A (ja) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| WO2019245590A1 (en) | 2018-06-18 | 2019-12-26 | Avista Pharma Solutions, Inc. | Chemical compounds |
| JP2021530487A (ja) * | 2018-07-11 | 2021-11-11 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその合成 |
| WO2020014465A1 (en) | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3917932A4 (en) | 2019-01-30 | 2022-09-28 | Avista Pharma Solutions, Inc. | CHEMICAL COMPOUNDS |
| CA3128346A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Synthetic process and novel intermediates |
| US11254675B2 (en) | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
| WO2021226162A1 (en) | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| CA3223173A1 (en) * | 2021-07-30 | 2023-02-02 | Raqualia Pharma Inc. | Crystalline forms |
| CN116478155B (zh) * | 2022-01-17 | 2025-06-13 | 洛阳惠中兽药有限公司 | 一种格拉匹伦及其中间体的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| PL373246A1 (en) * | 2002-04-12 | 2005-08-22 | Pfizer Inc. | Use of ep4 receptor ligands in the treatment of il-6 involved diseases |
-
2006
- 2006-03-01 DE DE602006014516T patent/DE602006014516D1/de active Active
- 2006-03-01 US US11/908,163 patent/US7960407B2/en active Active
- 2006-03-01 PL PL06710609T patent/PL1861400T3/pl unknown
- 2006-03-01 CN CN2006800079642A patent/CN101137656B/zh active Active
- 2006-03-01 EP EP06710609A patent/EP1861400B1/en active Active
- 2006-03-01 BR BRPI0608819A patent/BRPI0608819B8/pt active IP Right Grant
- 2006-03-01 ES ES06710609T patent/ES2344310T3/es active Active
- 2006-03-01 AU AU2006221699A patent/AU2006221699A1/en not_active Abandoned
- 2006-03-01 AT AT06710609T patent/ATE469150T1/de not_active IP Right Cessation
- 2006-03-01 RU RU2007133802/04A patent/RU2357968C1/ru active
- 2006-03-01 KR KR1020077020701A patent/KR100911073B1/ko active Active
- 2006-03-01 CA CA2600510A patent/CA2600510C/en active Active
- 2006-03-01 WO PCT/IB2006/000754 patent/WO2006095268A1/en not_active Ceased
- 2006-03-01 IN IN9939DEN2014 patent/IN2014DN09939A/en unknown
- 2006-03-01 MX MX2007011110A patent/MX2007011110A/es active IP Right Grant
- 2006-03-09 TW TW095108018A patent/TW200643021A/zh unknown
- 2006-03-09 AR ARP060100886A patent/AR055567A1/es unknown
- 2006-03-10 JP JP2006065731A patent/JP5069415B2/ja active Active
-
2007
- 2007-08-09 IL IL185145A patent/IL185145A0/en unknown
- 2007-09-03 ZA ZA200707568A patent/ZA200707568B/xx unknown
-
2018
- 2018-07-05 NL NL300944C patent/NL300944I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006249089A5 (OSRAM) | ||
| CA2600510A1 (en) | Crystal forms of an imidazole derivative | |
| RU2014105881A (ru) | Ансольваты солей норибогаина | |
| RU2009122241A (ru) | Твердые формы рацемического илапразола | |
| ME02275B (me) | Polimorfni oblik rotigotina | |
| JP2009536176A5 (OSRAM) | ||
| RU2598606C3 (ru) | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она | |
| JP2019503365A5 (OSRAM) | ||
| JP2011522816A5 (OSRAM) | ||
| JP2011528658A5 (OSRAM) | ||
| JP2014526503A5 (OSRAM) | ||
| JP2010514807A5 (OSRAM) | ||
| WO2019177975A1 (en) | Antibiotics effective for gram-negative pathogens | |
| JP2011527333A5 (OSRAM) | ||
| JP2016503010A5 (OSRAM) | ||
| JP2012502037A5 (OSRAM) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2023175694A5 (OSRAM) | ||
| RU2009133262A (ru) | Нападизилатная соль антагониста мускаринового мз-рецептора | |
| HRP20171511T1 (hr) | Ivabradin-hidroklorid, oblik iv | |
| JP2021073257A5 (OSRAM) | ||
| JP2020536893A5 (OSRAM) | ||
| JP2015522037A5 (OSRAM) | ||
| JP2010515682A5 (OSRAM) | ||
| JP2014530818A5 (OSRAM) |